NASDAQ: GTBPGt Biopharma Inc Stock
$0.62+0.07 (+12.73%)
Updated Nov 7, 2025
GTBP Price
$0.62
Fair Value Price
N/A
Market Cap
$2.21M
52 Week Low
$0.54
52 Week High
$4.10
P/E
-0.15x
P/B
0.77x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$9.40M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.49
Operating Cash Flow
-$10M
Beta
1.09
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
GTBP Overview
GT Biopharma, Inc. is a clinical-stage biopharmaceutical companydeveloping immuno-oncology products based on its proprietary Tri-specific Killer Engager fusion protein immune cell engager technology platform. Known as OXIS International, Inc. until 2017, GT Biopharma was incorporated in 1965 and is based in Brisbane, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine GTBP's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
GTBP
Ranked#273 of 483
Ranked#273 of 483
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.44 | A | |
| $105.98 | A | |
| $131.16 | A |
Be the first to know about important GTBP news, forecast changes, insider trades & much more!
GTBP News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how GTBP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GTBP is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
GTBP is good value based on its book value relative to its share price (0.77x), compared to the US Biotechnology industry average (4.81x)
P/B vs Industry Valuation
GTBP is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more GTBP due diligence checks available for Premium users.
Valuation
GTBP fair value
Fair Value of GTBP stock based on Discounted Cash Flow (DCF)
Price
$0.62
Fair Value
$2.08
Undervalued by
70.23%
GTBP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
GTBP price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.15x
Industry
239.51x
Market
44.6x
GTBP price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.77x
Industry
4.81x
GTBP is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
GTBP's financial health
Profit margin
Revenue
$0.0
Net Income
-$1.4M
Profit Margin
0%
GTBP's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$7.1M
Liabilities
$4.3M
Debt to equity
1.49
GTBP's short-term assets ($7.12M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GTBP's short-term assets ($7.12M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GTBP's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
GTBP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.0M
Investing
$0.0
Financing
$5.9M
GTBP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
GTBP vs Biotech Stocks
Gt Biopharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.